Bonum Certa Men Certa

The European Patent Convention (“EPC”) Does Not Allow Patenting of Life Itself

Wedding Invitation



Summary: Unless the underlying rules are respected and Europe's largest patent office actually follows the laws it's governed by, Europe's patent system won't promote innovation; the European Patent Office's decision on Alexion (patent application 3124029 rejected) is good news

BOTH the European Patent Office (EPO) and the U.S. Patent and Trademark Office (USPTO) still grapple with a question that should not even be asked. Why? Because the answer to it should be obvious. The American 35 U.S.C. €§ 101 is pretty clear about naturally-recurring phenomena and Europe has already spoken -- many times in fact -- about patents on life. If only Campinos and Battistelli actually obeyed the law...



Today's EPO not only tolerates patents on life and nature; it's also actively promoting software patents in Europe. The EPO is totally out of control!

To our surprise, and for a change, yesterday we saw this article from Phil Taylor (pharmaphorum). When patents are misused not for elevation of the sciences but for monopoly that enables ruinous price hikes in medicines this is what should happen:

The European Patent Office has blocked an attempt by Alexion to extend the patent protection for its blockbuster drug Soliris, setting up biosimilar competition from 2022.

The EPO delivered its verdict late last week but Alexion’s share price remained unscathed by the news, suggesting investors are confident that the company will be able to migrate revenues to its follow-up drug Ultomiris by that date.

In a brief Securities & Exchange Commission filing, Alexion said the EPO had rejected its attempt to extend two patents for Soliris (eculizumab) and it is considering an appeal.

It’s also facing a patent challenge to Soliris in the US from Amgen, which is developing a biosimilar version of the drug called ABP 959 and has petitioned the US Patent and Trademark Office (USPTO) to review Alexion’s intellectual property on the drug. It made the move after Alexion won an extension on its US patent life until 2027.

Soliris – a complement C5 inhibitor used to treat several rare diseases including paroxysmal nocturnal hemoglobinuria (PNH) and atypical haemolytic uremic syndrome (aHUS) – achieved sales of $1.94 billion in the first six months of the year, accounting for more than 80% of the biotech’s total sales in that period.


Kelly Davio (Center for Biosimilars, i.e. patent maximalists and monopolists) responded as follows to the EPO denying antibody patents:

Last week, Alexion disclosed in a filing to the US Securities and Exchange Commission that the European Patent Office (EPO) did not grant Alexion its request for 2 patents on its brand-name eculizumab product, Soliris, a C5 complement inhibitor that treats rare and ultrarare diseases.

The Form 8-K, dated September 5, indicates that the office declined to grant patent application 3124029, which covers a pharmaceutical composition comprising an antibody or antibody fragment binding to C5 for use in treating a patient with paroxysmal nocturnal hemoglobinuria (PNH), and patent application 3167888, which relates to the composition of matter of eculizumab.


This will probably be mentioned by patent maximalists' blogs such as IP Kat and Kluwer Patent Blog in days to come. Both like to promote patents on life/nature, especially in their current composition (they're both run by Big Pharma firms and their lawyers).

Mind this new IP Kat comment from "CRISPR scientist" (profiteer), who defends monopolies on life itself, ignoring health risks: "It would be feasible, but it would require a separate round of gene editing since no one could want to introduce a marker into the functional gene that is the subject of the first round of gene editing. The gene editing process is complicated, time consuming and costly. And every round of editing harbors the risk of additional unwanted modifications. So, can there really be a benefit if one has to perform an additional round of gene editing only for administrative sake? I shall think no. [...] I don't think that reasonable people are actually worried about their own health. Genetic material in the food you consume has very little possibility to influence your body. And I do doubt that it may cause food allergies. As the article correctly points out, the actual risk is what will happen to the ecosystem. I agree that heavy dependence on fertilizer or herbicides is detrimental. However, that is not what CRISPR is about. Gene editing is simply a stunning, secure and reliable technique to modify a plant's genome. Banning gene editing because it may cause harm in certain scenarios is much like banning operations per se simply because people may die if operated wrongly. We can't igonore the benefits that gene editing is bringing a world where we need more nurtrious food and crops that are able to resist climate change."

This is the classic propaganda/talking point from GMO proponents. We spent a lot of time and energy confronting these lies about a decade ago when we wrote a great deal about Monsanto, now part of Bayer in Germany.

Anyway, it's nice to see the EPO rejecting bad patents, probably showing a little bit of respect for the EPC, for a change...

Miquel Montañá has just mentioned the EPC in relation to a case outside the EPO's remit; he ought to take note of the fact that the EPO's management violates the EPC every day, rendering it moot! To quote yesterday's post from Montañá:

As readers are well aware, one of the difficult tasks when applying article 69 of the European Patent Convention (“EPC”) and its Protocol of Interpretation is to strike the right balance between “interpreting” the claims in the context of the specification, while, at the same time, avoiding “importing” features of the specification into the claims. A judgment of 12 February 2019 from the Barcelona Court of Appeal recently published has warned against the risk of using specification for the purpose of unduly restricting the scope of protection of the claims.

[...]

Interestingly, the Court of Appeal relied on the case law from the European Patent Office (“EPO”) Boards of Appeal (for example, T 1018/02, T 1395/07, T-544/89 and T-681/01) noting that, although they do not decide infringement cases, they do have to interpret the scope of protection of the claims when they examine validity.

Finally, the Court of Appeal added that, although in the past the Court had “read” in the claims features mentioned in the specification which were not explicitly mentioned in the claims, this was done in exceptional cases only, when the feature omitted in the claim was essential for the functioning of the invention. The Court of Appeal added that “But this is not the case, because the interpretation of the defendant and its expert relies solely and exclusively on the preferred embodiments disclosed in the drawings.”

All in all, the main teaching of this interesting judgment is that when applying article 69 of the EPC and its Protocol of Interpretation, care must be applied to avoid “importing” features of the specification into the claims.


Readers are well aware, as we've shown many examples lately, that European courts very often deviate from EPO judgments, which sometimes get delivered by the Boards that are afraid of the Office. This lack of independence is, in its own right, a gross violation of the EPC. ⬆

Recent Techrights' Posts

Soap Opera of NVIDIA Marketing in Mainstream Media (Overhyped GPUs and Mindless Buzzwords)
NVIDIA's shares lost about $100 in "value" (or 40% "market cap" decline) in 6-7 weeks
The Boss of Linus Torvalds Has Bad Taste, Takes More Money Connected to Traffickers of Underage Girls for Sexual Exploitation Under the Guise of "Tackling Fraud"
Nothing will ever teach Jim Zemlin that Jeffrey Epstein is bad [...] Even the wife of Mr. Epsteingate was wise enough to keep a distance from it. But not Mr. Zemlin, who profits from rehabilitating abusers.
 
IBM "Efficiency" is Working One's Way to the Bottom of the Remuneration Scale While Hiding the Stealth Layoffs
People still leaving
Forbes Already Stopped Being a News Site. Now It's a Spam and Propaganda Platform for "Paying Partners" (Companies).
news from Forbes became very scarce
Over at Tux Machines...
GNU/Linux news for the past day
IRC Proceedings: Thursday, November 19, 2026
IRC logs for Thursday, November 19, 2026
It's All About Restricted Boot and Microsoft
Garrett is working with Microsoft staff towards Microsoft agenda
Intercontinental Brigading - Part XXXXXVII - UK Isn't Part of the US or Russia
We have plenty to cover in the coming years
Update on Pocock v. Software in the Public Interest, Inc. (26-1766)
Case reassigned
Calling Frauds "Frauds" is Not Illegal
We are still getting the same vibe; Americans do not understand free speech, even if their country has a First Amendment
Everything is "AI" Now
"More Open Than Open [...] I am constantly amazed at the flexibility of this single word.”
Microsoft Web Sites Paint Mass Layoffs as Opportunities for Those Impacted, Mass Layoffs Alleged to Follow in January (to 'Kill Off' Survivors)
Keeping Up Appearances
Microsoft Outages Accelerate Migrations to Free Software
More than one major outage lately
Richard Stallman's Talks Next Month (Tech de Ciudad de México)
Right now is a very good time to promote Software Freedom because of recent world events
WSJ Leadership Institute as Marketing Spam for Slop and GAFAM/IBM PR
What the heck is "WSJ Leadership Institute"?
Links 19/11/2026: "So Many Crucial Services Are Going Down" and "Government Tech Debt is a National Security Risk" (Outages Blamed on Slop Frenzy)
Links for the day
Gemini Links 19/11/2026: Friends, Slop Harms Learning, and IBM Plex Lagrange Fontpacks
Links for the day
Links 19/11/2026: "Ignorance Has Taken Over" and "Apocalypse Now, Again"
Links for the day
Richard Stallman Still Insists "They" is Plural, Suggests "Perse" Instead
this week
New Video Explains Why Software Patents Are Evil ("Why Software Patents Spark So Much Frustration")
Maybe some patent examiners (who don't mind a Facebook URL) can take a look
Intercontinental Brigading - Part XXXXXVI - Never Showing Up for Their Own Hearings, Just Paying Hired Guns in London to Act as Fall Guys and Proxies With No Comprehension of the Technical Issues (and Sometimes by Bullying Our Lawyers)
Without any qualifications in the subject at hand
Compatible With Software of 30 Years Ago
Old is not bad, sometimes old is better
NVIDIA Corporation Does Not Look Healthy
The bubble will be hard to re-inflate
Gemini Links 19/11/2026: Thinking About Thinking and Discord
Links for the day
Over at Tux Machines...
GNU/Linux news for the past day
IRC Proceedings: Wednesday, November 18, 2026
IRC logs for Wednesday, November 18, 2026
Lots of IBM Layoffs in Slovakia This Year
Slovakia and Europe at large
There May be Little or No Future for IBM Consulting
IBM is believed to be run by parasites
At Least Three RMS Talks Next Month in Mexico (Richard Stallman Has 8+ Talks in a Month)
And also - possibly with slop - in social control media
Mass Layoffs at Salesforce Foretold by Techrights
Salesforce is dead meat and it's not alone
Gemini Links 18/11/2026: Creativity, MFA Hype, and Presto Music
Links for the day
Links 18/11/2026: More GAFAM/Apple 'Clown Computing' Outages and Deutsche Bank Leak, Banks' Downtimes
Links for the day
Today The Register MS Showed Loyalty to the Pyramid Scheme With Homage of Paid Spam About "AI"
The Register MS is disavowed by its founder, who died a few years ago (The Register MS didn't even mention this)
Staff Union of the European Patent Office (SUEPO) Plans General Assembly Next Week, Vote Planned to Approve 7+ More Months of Strikes
The "Agenda" is the same as what we showed yesterday, but the pattern of the actions varies somewhat
IBM's Red Hat a Microsoft Reseller (Second Day in a Row)
If you want a replacement for Microsoft, look somewhere other than Red Hat
After the Bubble Pops the "AI Experts" (Formerly "Data Scientists" or Whatever) Will Rebrand Themselves Again
Remember blockchains and metaverse?
Links 18/11/2026: "Fossil Fuel Companies Are Undermining Democracy" and "Lawyer Up, Elon"
Links for the day
Intercontinental Brigading - Part XXXXXV - Acts of Hypocrisy (Doing What You Accuse Others of Doing)
connected to my criticism of "Restricted Boot"
Mainstream and Establishment Media Trying to Connect "Open Source" to White-Collar Crimes and Scandals at Fraudulent NVIDIA
An associate us said that "MIT lies to smear OSS"
Lawfare Will Continue in 2027
We're dealing with defiant Microsofters who wrongly assume that accurate reporting that causes them distress somehow makes them entitled to money
On the Concept of Moral Obligations to Make the World a Better Place for Everybody
The world generally becomes better when more people challenge the status quo rather than bow down to masters
Nadella Talks About 60,000 Microsoft Workers Having to Decide Whether to Leave (in the Next 2-3 Weeks), They've Been Put on Notice
Some parts of Microsoft are poised for severe cuts
IBM Moved From Selling Technology to Selling Its Buildings
IBM is trying very hard to silence/crush critics
Staff Union of the European Patent Office (SUEPO) Looking to Extend Industrial Actions and Strikes to Almost 1.5 Years
It says a lot about the media that for 1.5 years staff is on strike in the second-largest organisation in Europe and the media pretends it's not happening
Richard Stallman's Talk in Quito This Week (At Least 5 Talks After That)
He's having a busy end of year
Gemini Links 18/11/2026: "Love For Old Devices" and New Software/Slop-ware Releases
Links for the day
Over at Tux Machines...
GNU/Linux news for the past day
IRC Proceedings: Tuesday, November 17, 2026
IRC logs for Tuesday, November 17, 2026